D.E. Shaw & Co’s Theriva Biologics TOVX Stock Holding History

D.E. Shaw & Co’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4	Closed	-$21K	–	3545
2017 Q1	$21K	Sell	4 -16	-80%	-$112K	﹤0.01%	3236
2016 Q4	$133K	Buy	+20	New	+$205K	﹤0.01%	3329

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

D.E. Shaw & Co's TOVX Position: Q2 2017 in Review

D.E. Shaw & Co sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 4 shares — an estimated $21K sold.

D.E. Shaw & Co first reported a position in TOVX in Q4 2016 and held it in 2 quarters. The position peaked at $133K in Q4 2016. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

D.E. Shaw & Co reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
D.E. Shaw & Co sold 4 Theriva Biologics shares in Q2 2017, an estimated $21K.
D.E. Shaw & Co first reported a position in Theriva Biologics in Q4 2016 and held it in 2 quarters.
D.E. Shaw & Co's Theriva Biologics position peaked at $133K in Q4 2016.
53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on D.E. Shaw & Co's 13F filing for Q2 2017, filed 14 Aug 2017.